|
A SCID-hu in vivo model of human Waldenström macroglobulinemia
|
|
CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia
|
|
CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia
|
|
Diagnosis and management of Waldenstrom's macroglobulinemia
|
|
Extended rituximab therapy in Waldenström's macroglobulinemia
|
|
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications
|
|
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
|
|
Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia
|
|
Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenstrom's macroglobulinemia
|
